The potential anti-inflammatory effect of tetrahydrobiopterin administration in renal mass reduction-induced chronic renal falure in rats

Saudi Medical Journal

Volumn 28, Issue 12, 2007, Pages 1803-1809

  Korish, Aida A ^a   Arafah, Maha M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INTERLEUKIN 6; MALONALDEHYDE; NITROUS OXIDE; TETRAHYDROBIOPTERIN; 5,6,7,8-TETRAHYDROBIOPTERIN; BIOPTERIN; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HISTOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RENAL PROTECTION; SHAM PROCEDURE; WISTAR RAT; ANIMAL; BLOOD; DISEASE MODEL; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY;

ANIMALS; BIOPTERIN; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MALONDIALDEHYDE; NEPHRECTOMY; RATS; RATS, WISTAR;

EID: 41149150390     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29: 658-668.
2. Bergstrom J, Heimburger O, Lindholm B. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol 1995; 6: 573.
3. Savica V, Calvani M, Benatti P, Santoro D. Carnitine system in uremic patients: Molecular and clinical aspects. Semin Nephrol 2004; 24: 464-468.
4. Yokoyama K, Tajima M, Yoshida H. Plasma pteridine concentration in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 1012-3106
5. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111: 1805-1812.
6. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 2001; 59: 407-414.
7. Menon V, Greene T, Wang X. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772.
8. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
9. Ducloux D, Bresson-Vautrin C. Kribs M, Abdelfatah A, Chalopin J-M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62 1417-1422.
10. Werner ER. Werner-Felmayer G, Wachter H, Mayer B. Biosynthesis of nitric oxide: Dependence on pterin metabolism, Rev Physiol Biochem Pharmacol 1996; 127: 97-123.
11. Thony B, Auerbach G, Blau N. Tetrahydrobiopetrin biosynthesis, regeneration and function. Biochem 2000; 347 (pt 1). 1-16.
12. Kaspers B, Gutlich M, Witter K, Losch U, Goldberg M, Ziegler I. Coordinate induction of tetrahydrobiopetrin synthesis and nitric oxide cyclohydrolase I activity. Comp Biochem Physiol B Biochem Mol Biol 1997; 117: 209-215.
13. Gupta S, Fredereicks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997; 349: 1252-1253.
14. Kakoki M, Hirata Y, Hayakawa H. Effects of tetrahydrobiopetrin on endothelial dysfunction in rats with ischemic acute renal failure. J Am Soc Nephrol 2000; 11: 301-309
15. Cosentino F, Katusic Z. Tetrahydrobiopetrin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91: 139-144.
16. Cosentino F, Patton S, Uscio LV. Tetrahydrobiopetrin alters superoxide and nitric oxide release in hypertensive rats, J Clin Invest 1998; 101: 1530-1537.
17. Weyer RMF, van Dam T, van Rijn HJ. Tetrahydrobiopetrin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997; 237: 340-344.
18. Kimmel PL, Phillips TM, Simmens SJ. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54: 236-244.
19. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I. Inflammation is associated with carotid atheoclerosis in dialysis patients, J Hypertens 2000, 18: 1207-1213.
20. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55; 648-658.
21. Stenvinkel P Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L. Strong association between malnutrition. inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
22. Rao M, Jaber BL. Vaidyanathapuram, S. Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: Association or cause and effect? Seminars in Dialysis 2006; 19: 129-135.
23. Bistrain BR, Schwartz J. Istfan NW. Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation. Proc Soc Exp Biol Med 1992; 2000: 220-223.
24. Buttery LDK, Springall DR, Chester AH, Evans TI, Standfield N, Parums DV, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 77-85
25. Wink DA, Cook JA, Kim SY, Vodovotz Y, Pacelli R, Krishna MC, et al. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. J Biol Chem 1997; 272: 11147-11151.
26. Fried L, Solomon C, Shlipak M. Inflammatory and prothrombotic markers and the progression of low disease in elderly individuals. J Am Soc Nephrol 2005; 16: 2431-2438.
27. Oslen JL: Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1993; 44: 445-450.
28. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplementation with tetrahydrobiopterin suppresses the development of hypetension in spontaneously hypertensive rats. Hypertension 2001; 38: 1044-1048.
29. Chander P, Gealekman O, Sergey V, Brodsky Y. Elitok S. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: Prevention by chronic therapy with a peroxynitrite scavenger ebselen J Am Soc Neprol 2004; 15: 2391-2403.
30. Yagi K, A simple fluormetric assay of lipid peroxide in blood plasma. Biochem Med 1976; 15: 212-216.
31. Varley H, Gowenlock AH, Macumurry JR. Vareley's practical clinical biochemistry 6th ed. London (UK): William Heinmmann Medical Book Ld; 1988.
32. Yeun JY, Levine RA. Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
33. Stenvinkel P, Heimburger O, Paultre F, Diczfilusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
34. de Maat MP, Trion A. C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004; 15: 651-657.
35. Kuncio GS, Neilson EG, Haverty T. Merchanisms of tubulointerstitial fibrosis. Kidney Int 1991; 39: 550-556.
36. Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998; 54. 992-994.
37. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-549.
38. Wang CH, Li SH, Weisel RD, Fedak PW. Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury. Am J Physiol Requl Integr Comp Physiol 2005; 289: R299-R304.
39. Shen RS. Inhibition of luminol-enhanced chemiluminescene by reduced pterins. Arch Biochem Biophys 1994; 310: 60-63.
40. Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2/calmodulindependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992: 281: 627-630.
41. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992; 267: 24173-24176.
42. Stuehr DJ, Cho HJ, Kwon NS Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991; 88: 7773-7777.
43. Kojima S, Ona S, Iizuka I, Arai T, Mori H, Kubota K. Antioxidative activity of 5,6,7,8-tetrahydrobioptrin and its inhibitory effect on paraquat-induced cell toxicity in cultured rat hepatocytes. Free Radic Res 1995; 23; 419-430.
44. Shimizu S, Ishii M, Momose K, Yamamoto T. Role of tetrahydrobiopterin in the function of nitric oxide synthase, and its cytoprotective effect (Review). Int J Mol Med 1998; 49; 533-540
45. Mittermayer F, Pleiner J, Schalller G, Zorn S. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005; 289: H1752-H1757.
46. Podjarny E, Hasdan G, Bernheim J. Rashid G, Green J, Korzets Z, et al. Effect of chronic tetrahydrobiapterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats. Nephrol Dial Transplant 2004; 19: 2223-2227.
47. Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998; 54; 992-994.
48. Cai H. Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
49. Vasquez-Vivar J, Kalyanaraman B, Marstasek P. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-9225.